Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.62
+0.29 (3.42%)
At close: May 29, 2025, 4:00 PM
8.62
0.00 (0.06%)
After-hours: May 29, 2025, 4:08 PM EDT
Zevra Therapeutics Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Zevra Therapeutics stock ranges from a low of $18 to a high of $25. The average analyst price target of $22.29 forecasts a 158.73% increase in the stock price over the next year.
Price Target: $22.29 (+158.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +190.19% | May 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +190.19% | Mar 13, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +155.37% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +132.15% | Mar 13, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $17 → $18 | Buy | Maintains | $17 → $18 | +108.94% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
88.96M
from 23.61M
Increased by 276.77%
Revenue Next Year
165.60M
from 88.96M
Increased by 86.15%
EPS This Year
0.67
from -2.28
EPS Next Year
0.59
from 0.67
Decreased by -11.79%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 104.4M | 222.6M | 357.0M | ||
| Avg | 89.0M | 165.6M | 251.8M | ||
| Low | 56.6M | 112.3M | 173.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 342.0% | 150.2% | 115.6% | ||
| Avg | 276.8% | 86.1% | 52.0% | ||
| Low | 139.9% | 26.2% | 4.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.51 | 1.30 | 2.99 | ||
| Avg | 0.67 | 0.59 | 1.74 | ||
| Low | -0.64 | -0.04 | 0.86 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 93.0% | 402.9% | ||
| Avg | - | -11.8% | 192.8% | ||
| Low | - | - | 44.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.